NCT06487221View on ClinicalTrials.gov

Avutometinib and Defactinib in Diffuse Gastric Cancer

PHASE2RecruitingINTERVENTIONAL

Enrollment

27

Participants

Timeline

Start Date

October 28, 2024

Primary Completion Date

November 30, 2028

Study Completion Date

May 30, 2029

Conditions

Gastric CancerStomach Cancer

Interventions

DRUG

Avutometinib

3.2mg orally

DRUG

Defactinib

200 mg orally

Trial Locations (1)

10032

RECRUITING

Columbia University Irving Medical Center, New York

Sponsors

Collaborators (1)

Verastem Oncology

All Listed Sponsors

collaborator

Verastem Oncology

UNKNOWN

lead

Ryan H. Moy, MD, PhD

OTHER

NCT06487221 - Avutometinib and Defactinib in Diffuse Gastric Cancer | Biotech Hunter | Biotech Hunter